Jussuf T Kaifi1, Miriam Kunkel2, Junjia Zhu3, David T Dicker2, Niraj Gusani4, Zhaohai Yang5, Nabeel E Sarwani6, Guangfu Li1, Eric T Kimchi1, Kevin F Staveley-O'Carroll1, Wafik S El-Deiry2. 1. Division of Surgical Oncology; Hollings Cancer Center; Medical University of South Carolina; Charleston, SC USA. 2. Laboratory of Translational Oncology and Experimental Cancer Therapeutics; Division of Hematology/Oncology; Department of Medicine; Penn State Hershey Cancer Institute; Pennsylvania State University; Hershey, PA USA. 3. Department of Public Health Sciences; Penn State Hershey Cancer Institute; Pennsylvania State University; Hershey, PA USA. 4. Section of Surgical Oncology; Department of Surgery; Penn State Hershey Cancer Institute; Pennsylvania State University; Hershey, PA USA. 5. Department of Pathology; Penn State Hershey Cancer Institute; Pennsylvania State University; Hershey, PA USA. 6. Department of Radiology, Penn State Hershey Cancer Institute; Pennsylvania State University; Hershey, PA USA.
Abstract
BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when combining both genders. Circulating tumor cells (CTCs) are a prognostic marker for stage IV CRC patients. We hypothesized that CTC quantity varies among stage IV CRC populations. METHODS: Blood (7.5 ml) was prospectively collected from 90 stage IV CRC patients. EpCAM(+) CTCs were analyzed with the FDA-approved CellSearch(®) system. CRC tumors were immunohistochemically stained for EpCAM expression. Imaging and clinicopathological data were collected. Statistical analysis was performed using correlation analysis, Kruskal-Wallis, Fisher exact, and log-rank test. RESULTS: CTCs were detectable in 36/90 (40%) patients. Diffuse CRC metastases were associated with the highest CTC prevalence (24/40 [60%]), in contrast to limited lung (2/19 [11%]) or liver (10/31 [32%]) metastases (P = 0.027). The overall mean CTC number was 2.0 (range 0-56.3). The mean CTC number in patients with diffuse metastases was significantly higher (3.7 [SEM ± 1.7, range 0-56.3]) than with limited lung metastases (0.1 [± 0.1; range 0-1]) or liver metastases (0.9 [± 0.3, range 0-7.0]) (P = 0.001). CRC tumors were consistently expressing EpCAM. CTC numbers did not correlate with serum CEA levels or other routine clinical parameters (P = N.S.). Patients with diffuse metastases had the poorest overall survival (P = 0.0042). CONCLUSIONS: CRC patients with diffuse metastases have the highest number of CTCs, in contrast to limited metastases to the liver or lungs. Future studies should correlate CTCs with recurrence patterns in patients with resected CRC lung or liver metastases to investigate whether CTCs represent micrometastatic disease causing early relapses.
BACKGROUND:Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when combining both genders. Circulating tumor cells (CTCs) are a prognostic marker for stage IV CRC patients. We hypothesized that CTC quantity varies among stage IV CRC populations. METHODS: Blood (7.5 ml) was prospectively collected from 90 stage IV CRC patients. EpCAM(+) CTCs were analyzed with the FDA-approved CellSearch(®) system. CRC tumors were immunohistochemically stained for EpCAM expression. Imaging and clinicopathological data were collected. Statistical analysis was performed using correlation analysis, Kruskal-Wallis, Fisher exact, and log-rank test. RESULTS: CTCs were detectable in 36/90 (40%) patients. Diffuse CRC metastases were associated with the highest CTC prevalence (24/40 [60%]), in contrast to limited lung (2/19 [11%]) or liver (10/31 [32%]) metastases (P = 0.027). The overall mean CTC number was 2.0 (range 0-56.3). The mean CTC number in patients with diffuse metastases was significantly higher (3.7 [SEM ± 1.7, range 0-56.3]) than with limited lung metastases (0.1 [± 0.1; range 0-1]) or liver metastases (0.9 [± 0.3, range 0-7.0]) (P = 0.001). CRC tumors were consistently expressing EpCAM. CTC numbers did not correlate with serum CEA levels or other routine clinical parameters (P = N.S.). Patients with diffuse metastases had the poorest overall survival (P = 0.0042). CONCLUSIONS: CRC patients with diffuse metastases have the highest number of CTCs, in contrast to limited metastases to the liver or lungs. Future studies should correlate CTCs with recurrence patterns in patients with resected CRC lung or liver metastases to investigate whether CTCs represent micrometastatic disease causing early relapses.
Authors: Henry K Lin; Siyang Zheng; Anthony J Williams; Marija Balic; Susan Groshen; Howard I Scher; Martin Fleisher; Walter Stadler; Ram H Datar; Yu-Chong Tai; Richard J Cote Journal: Clin Cancer Res Date: 2010-09-28 Impact factor: 12.531
Authors: Long R Jiao; Christos Apostolopoulos; Jimmy Jacob; Richard Szydlo; Natalia Johnson; Nicole Tsim; Nagy A Habib; R Charles Coombes; Justin Stebbing Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Michal Mego; Ugo De Giorgi; Shahenaah Dawood; Xuemei Wang; Vicente Valero; Eleni Andreopoulou; Beverly Handy; Naoto T Ueno; James M Reuben; Massimo Cristofanilli Journal: Int J Cancer Date: 2010-11-28 Impact factor: 7.396
Authors: Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz Journal: Nat Med Date: 2007-07-31 Impact factor: 53.440
Authors: Evi S Lianidou; Dimitris Mavroudis; Georgia Sotiropoulou; Sophia Agelaki; Klaus Pantel Journal: Breast Cancer Res Date: 2010-07-23 Impact factor: 6.466
Authors: Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: Lixin Zhang; Lon D Ridgway; Michael D Wetzel; Jason Ngo; Wei Yin; Disha Kumar; Jerry C Goodman; Morris D Groves; Dario Marchetti Journal: Sci Transl Med Date: 2013-04-10 Impact factor: 17.956
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: R Mastronicola; C Berteau; Q Tu; S Cortese; J Guillet; B Phulpin; P Gangloff; L Bezdetnaya; J-L Merlin; G Faure; G Dolivet Journal: Eur Arch Otorhinolaryngol Date: 2015-01-30 Impact factor: 2.503
Authors: Jussuf T Kaifi; Miriam Kunkel; David T Dicker; Jamal Joude; Joshua E Allen; Avisnata Das; Junjia Zhu; Zhaohai Yang; Nabeel E Sarwani; Guangfu Li; Kevin F Staveley-O'Carroll; Wafik S El-Deiry Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Jussuf T Kaifi; Miriam Kunkel; Avisnata Das; Ramdane A Harouaka; David T Dicker; Guangfu Li; Junjia Zhu; Gary A Clawson; Zhaohai Yang; Michael F Reed; Niraj J Gusani; Eric T Kimchi; Kevin F Staveley-O'Carroll; Si-Yang Zheng; Wafik S El-Deiry Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Jussuf T Kaifi; Guangfu Li; Gary Clawson; Eric T Kimchi; Kevin F Staveley-O'Carroll Journal: Cancer Biol Ther Date: 2016-04-05 Impact factor: 4.742
Authors: Z S Lalmahomed; B Mostert; W Onstenk; J Kraan; N Ayez; J W Gratama; D Grünhagen; C Verhoef; S Sleijfer Journal: Br J Cancer Date: 2015-01-06 Impact factor: 7.640
Authors: Nikhil Chauhan; Mary F Mulcahy; Riad Salem; Al B Benson Iii; Eveline Boucher; Janet Bukovcan; David Cosgrove; Chantal Laframboise; Robert J Lewandowski; Fayaz Master; Bassel El-Rayes; Jonathan R Strosberg; Daniel Y Sze; Ricky A Sharma Journal: JMIR Res Protoc Date: 2019-01-17